Medicines Co., SymBio deal

The Medicines Co. granted SymBio an exclusive license to develop and commercialize Ionsys fentanyl iontophoretic transdermal system in Japan. The needle-free, patient-controlled, preprogrammed delivery system of fentanyl, a mu opioid receptor (MOR; OPRM1) agonist, is approved in the U.S. for the short-term management of acute postoperative pain in adult patients requiring opioid analgesia in the hospital. The Medicines Co. received $10 million up front and is eligible for regulatory and commercial milestones, plus royalties. ...